Zura Bio bets on dual IL-17 and BAFF inhibition across three immune-mediated disease
Explore how Zura Bio’s expanded tibulizumab Phase 2 program could change treatment development in HS and systemic sclerosis.
Pharma & Biotech
Pharma & Biotech
Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Pharma & Biotech
Aisa Pharma’s AISA-021 shows mixed but promising signals in systemic sclerosis-associated Raynaud’s phenomenon
Aisa Pharma’s AISA-021 shows promising Phase 2 signals in systemic sclerosis Raynaud’s. Discover what the RECONNOITER data could mean for future treatment.